Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog Alfa (Activated) in Treatment of Episodic Bleeding in Subjects With Inherited Bleeding Disorders

Next Previous
X
Search
Trial Profile

Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog Alfa (Activated) in Treatment of Episodic Bleeding in Subjects With Inherited Bleeding Disorders

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Marzeptacog alfa (Primary) ; Marzeptacog alfa (Primary)
  • Indications Factor VII deficiency; Haemophilia A; Thrombasthenia
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms MAA-202
  • Sponsors Catalyst Biosciences

    • Most Recent Events

    • 02 Jan 2023 This trial has been discontinued in Italy , according to European Clinical trials database.
    • 06 Dec 2021 Status changed from recruiting to discontinued as per company decision (not a safety issue)
    • 06 May 2021 According to a Catalyst Biosciences media release, first patient has been dosed in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top